Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptinyx Inc (NQ: APTX )

0.2590 -0.0131 (-4.81%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 2, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 240,275
Open 0.2673
Bid (Size) 0.2520 (76)
Ask (Size) 0.2750 (100)
Prev. Close 0.2721
Today's Range 0.2510 - 0.2724
52wk Range 0.2000 - 3.760
Shares Outstanding 67,715,718
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience
From Aptinyx Inc.
Via Business Wire

Performance

YTD
-90.62%
-90.62%
1 Month
-0.38%
-0.38%
3 Month
-34.25%
-34.25%
6 Month
-38.30%
-38.30%
1 Year
-88.64%
-88.64%

More News

Read More
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights
From Aptinyx Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant
From Aptinyx Inc.
Via Business Wire
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
From Aptinyx Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies
From Aptinyx Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022
Via Benzinga
What 4 Analyst Ratings Have To Say About Aptinyx
Via Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Via Benzinga
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Aptinyx Shares Plummet As Mid-Stage Fibromyalgia Study Missed Primary Endpoint
Via Benzinga
Here's Why Aptinyx Stock Is Lower By Over 30% Friday
Via Benzinga
Aptinyx's Chronic Pain Candidate Fails To Top Placebo In Mid-Stage Study
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia
From Aptinyx Inc.
Via Business Wire
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.